ATYR Key Statistics, Chart & Performance
The current stock price of ATYR is 0.7831 USD. In the past month the price increased by 11.02%. In the past year, price decreased by -80.32%.
ATYR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ATYR
Company Profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Company Info
ATYR PHARMA INC
10240 Sorrento Valley Road, Suite 300
San Diego CALIFORNIA US
Employees: 56
Phone: 18587318389
ATYR PHARMA INC / ATYR FAQ
What does ATYR PHARMA INC do?
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
What is the current price of ATYR stock?
The current stock price of ATYR is 0.7831 USD. The price increased by 5.11% in the last trading session.
Does ATYR PHARMA INC pay dividends?
ATYR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATYR stock?
ATYR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ATYR stock?
ATYR stock is listed on the Nasdaq exchange.
How is the market expecting ATYR stock to perform?
16 analysts have analysed ATYR and the average price target is 6.48 USD. This implies a price increase of 728.02% is expected in the next year compared to the current price of 0.7831.
Can you provide the growth outlook for ATYR PHARMA INC?
The Revenue of ATYR PHARMA INC (ATYR) is expected to decline by -40.54% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ATYR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ATYR. When comparing the yearly performance of all stocks, ATYR is a bad performer in the overall market: 90.93% of all stocks are doing better.
ATYR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATYR. The financial health of ATYR is average, but there are quite some concerns on its profitability.
ATYR Financial Highlights
Over the last trailing twelve months ATYR reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 11.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.44% | ||
| ROE | -93.63% | ||
| Debt/Equity | 0 |
ATYR Forecast & Estimates
16 analysts have analysed ATYR and the average price target is 6.48 USD. This implies a price increase of 728.02% is expected in the next year compared to the current price of 0.7831.
For the next year, analysts expect an EPS growth of 1.68% and a revenue growth -40.54% for ATYR